The correct IUPAC name for the given compound has to be chosen from the given options. Concept Introduction: IUPAC nomenclature for alkene : There are about eight rules to be followed in giving IUPAC name for alkene. The suffix –ane has to be replaced with the suffix –ene. This is used to indicate the presence of double bond. The longest continuous chain of carbon atoms has to be chosen that contains both carbon atoms of the double bond. The parent carbon chain has to be numbered in a way so that the numbering begins at the end near to the double bond. In case if the double bond is equidistant from both ends, then numbering has to be done from the end that is closer to substituents. The position of the double bond has to be given a single number which is lower‑numbered carbon atom that is present in the double bond. Suffixes like –diene, -triene, -tetrene, and so on are used when the compound contains more than one double bond. In case of cycloalkenes which do not have any substitution, the numbering is not needed to locate the double bond because the bond is assumed to be between the carbons 1 and 2. In case if substituents are present in cycloalkene, then the double‑bonded carbon atoms are numbered 1 and 2 in a direction where the substituent gets the lower number. If the cycloalkenes contain more than one double bond, then one double bond is assigned the numbers 1 and 2 followed by the other double bond so that the lowest number possible is given.

Question

Want to see the full answer?

Answer 1

Question

Chapter 13.3, Problem 2QQ

Interpretation Introduction

Interpretation:

The correct IUPAC name for the given compound has to be chosen from the given options.

Concept Introduction:

IUPAC nomenclature for alkene: There are about eight rules to be followed in giving IUPAC name for alkene.

The suffix –ane has to be replaced with the suffix –ene. This is used to indicate the presence of double bond.

The longest continuous chain of carbon atoms has to be chosen that contains both carbon atoms of the double bond.

The parent carbon chain has to be numbered in a way so that the numbering begins at the end near to the double bond. In case if the double bond is equidistant from both ends, then numbering has to be done from the end that is closer to substituents.

The position of the double bond has to be given a single number which is lower‑numbered carbon atom that is present in the double bond.

Suffixes like –diene, -triene, -tetrene, and so on are used when the compound contains more than one double bond.

In case of cycloalkenes which do not have any substitution, the numbering is not needed to locate the double bond because the bond is assumed to be between the carbons 1 and 2.

In case if substituents are present in cycloalkene, then the double‑bonded carbon atoms are numbered 1 and 2 in a direction where the substituent gets the lower number.

If the cycloalkenes contain more than one double bond, then one double bond is assigned the numbers 1 and 2 followed by the other double bond so that the lowest number possible is given.

Expert Solution & Answer

Want to see the full answer?

Check out a sample textbook solution

See solution

Students have asked these similar questions

19. On the diagram below a. Label the three pictures as: DNA; polypeptide; or RNA. b. Label the arrows as: translation or transcription/RNA processing. c. Add the following details to the diagram. Promoter region TATA box Transcription start site Transcription terminator Intron (A,B,C,D) Exons (1,2,3,4,5) Splice sites 5' cap 5' UTR (untranslated region) 3' poly A tail 3' UTR (untranslated region) Translational start (AUG) Translational stop (UGA, UAG, or UAA) N and C ends of polypeptide 0000

Match the letter labels in the figure below to the terms. Some letter labels are not used. MNNNNNNIN M C B A M D F E H K G 8

The diagram below illustrates a quorum sensing pathway from Staphylococcus aureus. Please answer the following questions. 1. Autoinduction is part of the quorum sensing system. Which promoter (P2 or P3) is critical for autoinduction? 2)This staphylococcus aureus grows on human wounds, causing severe infections. You would like to start a clinical trial to treat these wound infections. Please describe: a) What molecule do you recommend for the trial. Why? b) Your trial requires that Staphylococcus aureus be isolated from the wound and submitted to genome sequencing before admittance. Why? What are you testing for? 3) If a mutation arises where the Promoter P3 is constitutively active, how would that influence sensitivity to AIP? Please explain your rationale. 4) This pathway is sensitive to bacterial cell density. Describe two separate mutation that would render the pathway active independent of cell density. Briefly explain your rationale. Mutation 1 Mutation 2